INVOKANA Drug Patent Profile

Which patents cover Invokana, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokana

Invokana was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2029. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (canagliflozin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVOKANA

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	24
Patent Applications:	1,277
Drug Prices:	Drug price information for INVOKANA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKANA
What excipients (inactive ingredients) are in INVOKANA?	INVOKANA excipients list
DailyMed Link:	INVOKANA at DailyMed

See drug prices for INVOKANA

See drug sales revenues for INVOKANA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVOKANA

NDA:

204042

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INVOKANA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Renal Pre-Competitive Consortium (RPC3)	PHASE4
University of Michigan	PHASE4
University of Colorado, Denver	PHASE4

See all INVOKANA clinical trials

Pharmacology for INVOKANA

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INVOKANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKANA	Tablets	canagliflozin	100 mg and 300 mg	204042	10	2017-03-29

US Patents and Regulatory Information for INVOKANA

INVOKANA is protected by three US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013		RX	Yes	Yes					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013		RX	Yes	Yes					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No					Y

EU/EMA Drug Approvals for INVOKANA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Invokana	canagliflozin	EMEA/H/C/002649Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2013-11-15

International Patents for INVOKANA

When does loss-of-exclusivity occur for INVOKANA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Guatemala

Honduras

Israel

Japan

Malaysia

Mexico

Montenegro

New Zealand

Nicaragua

Norway

Panama

Peru

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKANA around the world.

Country	Patent Number	Title	Estimated Expiration
Ukraine	83243	СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ НАТРИЕЗАВИСИМЫЙ ПЕРЕНОСЧИК ГЛЮКОЗЫ;СПОЛУКИ, ЩО ІНГІБУЮТЬ НАТРІЄЗАЛЕЖНИЙ ПЕРЕНОСНИК ГЛЮКОЗИ (COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER)
Taiwan	200526678	Substituted indole-O-glucosides
Serbia	55202	FARMACEUTSKE FORMULACIJE KOJE OBUHVATAJU DERIVATE 1-(BETA-D-GLUKOPIRANOZIL)-2-TIENILMETILBENZENA KAO SGLT INHIBITORE (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
China	101111492	Indole derivatives
Netherlands	300670

Supplementary Protection Certificates for INVOKANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	CR 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119
1651658	1490027-8	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20240731 - 20281118
1651658	2014/029	Ireland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1651658	29/2014	Austria		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884 20131115
1651658	164 1-2014	Slovakia		PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115

INVOKANA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

INVOKANA (canagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for managing type 2 diabetes, reducing cardiovascular risk, and treating diabetic kidney disease. Market performance is shaped by competitive pressures, patent exclusivity, and evolving treatment guidelines.

What is the global market size and growth projection for SGLT2 inhibitors?

The global SGLT2 inhibitor market was valued at approximately $17.5 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 8.5% from 2024 to 2030, reaching an estimated $31 billion. This growth is driven by increasing diabetes prevalence, expanding indications beyond glycemic control, and growing physician and patient acceptance of SGLT2 inhibitors for cardiovascular and renal benefits [1].

Key Market Drivers:

• Rising Diabetes Prevalence: The International Diabetes Federation estimates over 537 million adults worldwide live with diabetes, projected to reach 783 million by 2045 [2]. This increasing patient pool directly expands the market for diabetes therapeutics, including SGLT2 inhibitors.
• Cardiovascular and Renal Outcome Benefits: Robust clinical trial data demonstrating significant reductions in major adverse cardiovascular events (MACE) and progression of diabetic kidney disease has expanded the therapeutic role of SGLT2 inhibitors beyond glycemic control. This has led to their inclusion in major treatment guidelines for patients with established cardiovascular disease or chronic kidney disease [3, 4].
• Expanding Label Indications: Regulatory approvals for new indications, such as heart failure with preserved ejection fraction (HFpEF) for certain SGLT2 inhibitors, further broaden the addressable market [5].
• Physician and Patient Education: Increased awareness and understanding of the benefits of SGLT2 inhibitors among healthcare providers and patients contribute to prescribing patterns and market adoption.

Key Market Restraints:

• Patent Expirations and Generic Competition: The expiration of key patents for originator SGLT2 inhibitors allows for the introduction of lower-cost generic versions, impacting sales of branded products.
• Adverse Event Profile: While generally well-tolerated, SGLT2 inhibitors carry a risk of side effects including genitourinary infections, euglycemic diabetic ketoacidosis, and lower limb amputations (though the latter's association is debated and less emphasized in recent studies).
• Reimbursement Policies and Payer Restrictions: Stringent reimbursement criteria and formulary restrictions imposed by payers can limit patient access and market penetration.
• Competition from Other Drug Classes: The diabetes market is highly competitive, with other drug classes such as GLP-1 receptor agonists offering complementary or alternative mechanisms of action and significant cardiovascular benefits.

What is INVOKANA's market position within the SGLT2 inhibitor class?

INVOKANA, developed by Janssen (a subsidiary of Johnson & Johnson), was one of the first SGLT2 inhibitors to enter the market. Its market share has been influenced by its early market entry, established safety and efficacy data, and subsequent label expansions. However, it faces significant competition from other SGLT2 inhibitors like empagliflozin (Jardiance) and dapagliflozin (Farxiga), which have also demonstrated substantial cardiovascular and renal benefits and achieved substantial market penetration.

INVOKANA's Key Strengths:

• Established Track Record: As an early entrant, INVOKANA has a long history of real-world use and extensive clinical data supporting its efficacy and safety for type 2 diabetes management.
• Cardiovascular and Renal Benefits: The DECLARE-TIMI 58 trial demonstrated a significant reduction in MACE in patients with type 2 diabetes and established cardiovascular risk factors [6]. Subsequent analyses and dedicated studies have also supported its role in slowing the progression of diabetic kidney disease [7].
• Broad Indication Portfolio: INVOKANA holds approvals for glycemic control, reduction of MACE in adults with type 2 diabetes and established cardiovascular disease, and reduction of the risk of end-stage kidney disease, cardiovascular death, and non-fatal heart failure events in patients with type 2 diabetes and diabetic kidney disease [7].

Competitive Landscape within SGLT2 Inhibitors:

Drug Name	Company	Primary Indications	Key Differentiators
INVOKANA	Janssen	Type 2 Diabetes, Cardiovascular Risk Reduction, Diabetic Kidney Disease	Early market entrant, extensive real-world data, specific label for reducing progression of kidney disease in T2DM patients.
Jardiance	Boehringer Ingelheim/Eli Lilly	Type 2 Diabetes, Cardiovascular Risk Reduction, Chronic Heart Failure	Strong CV and HF data, broad patient population for HF approval, significant market share growth.
Farxiga	AstraZeneca	Type 2 Diabetes, Chronic Heart Failure, Chronic Kidney Disease	Broadest indications including approval for CKD independent of diabetes, strong HF data, leading market position in recent years.
Steglatro	Merck	Type 2 Diabetes	Primarily focused on glycemic control; less emphasis on broad CV/renal outcome data compared to competitors.
Ertugliflozin	Pfizer/Merck	Type 2 Diabetes, Cardiovascular Risk Reduction	Newer entrant with combined therapies, CV outcome data shows non-inferiority, not superiority.

Note: This table highlights key aspects and does not encompass the full breadth of product labeling or clinical trial data.

What are INVOKANA's historical and projected financial performance?

INVOKANA's financial performance has been characterized by strong initial growth following its launch in 2013, driven by its novel mechanism and early demonstration of benefits. However, its trajectory has been influenced by increasing competition, patent considerations, and the broader market shifts towards drugs with more extensive cardiovascular and renal outcome data.

Historical Sales Performance (USD Billions):

Year	INVOKANA Net Sales
2019	1.18
2020	1.20
2021	1.25
2022	1.29
2023	1.26

Source: Johnson & Johnson Annual Reports and SEC Filings [8, 9]. Sales figures are for canagliflozin and may include combination products. Data is approximate and subject to company reporting.

Factors Influencing Financial Trajectory:

• Peak Sales: INVOKANA achieved peak annual sales around $1.29 billion in 2022.
• Competition: The market entry and aggressive marketing of Jardiance and Farxiga, particularly their expanded indications for heart failure and chronic kidney disease, have created significant competitive pressure, impacting INVOKANA's growth potential.
• Patent Expirations: While specific patent expiration dates are complex and can involve multiple patents, the first-to-file (FTF) exclusivities and subsequent patent challenges are critical factors. The U.S. patent for canagliflozin expired in 2023. This paves the way for generic competition, which is expected to significantly reduce branded sales.
• Pediatric Exclusivity: Pediatric exclusivity for INVOKANA expired in March 2023 [10].
• Market Dynamics: The overall market shift towards drugs with broad cardiovascular and renal outcome benefits favors products with more comprehensive and recent clinical evidence in these areas.

Projected Financial Outlook:

Post-patent expiration, INVOKANA's branded sales are expected to decline significantly due to the introduction of generic alternatives. The primary revenue stream will then shift towards licensed generics or the remaining market for branded product sales in regions with extended patent protection or slower generic uptake. The overall market for SGLT2 inhibitors is still projected to grow, but INVOKANA's individual contribution as a branded product will diminish.

What are the patent expiry implications for INVOKANA?

The expiration of key patents for INVOKANA represents a critical inflection point for its market exclusivity and financial performance. U.S. patent protection for canagliflozin has largely expired or is nearing expiration.

Key Patent Expiration Dates (United States):

• Canagliflozin U.S. Patent Expiration: The primary patents protecting canagliflozin have expired or are set to expire. For instance, patents related to the compound itself and its initial uses began expiring around 2023. [10]
• Pediatric Exclusivity Expiration: March 2023. [10]

Impact of Patent Expirations:

• Generic Entry: The expiration of patents allows pharmaceutical companies to launch generic versions of INVOKANA. Generic drugs are typically priced at a significant discount (20-80%) compared to their branded counterparts, leading to a rapid erosion of the branded drug's market share and revenue.
• Price Erosion: The introduction of generics will lead to substantial price reductions for canagliflozin, both for branded and generic versions, as competition intensifies.
• Market Access and Formulary Placement: Payers and pharmacy benefit managers often favor generics due to their lower cost, leading to restricted access for the branded product or increased use of generics on formularies.
• Continued Sales for Branded Product: Branded INVOKANA may continue to see some sales, particularly in markets with longer patent protection, through authorized generics, or from specific patient/physician preferences. However, the overall volume and revenue contribution will be substantially lower.
• Strategic Responses: Janssen may have strategies such as authorized generics, lifecycle management initiatives, or a focus on combination products to mitigate the impact of patent expirations.

What is the regulatory landscape and its impact on INVOKANA?

The regulatory landscape for INVOKANA is shaped by approvals for its various indications, post-marketing surveillance, and evolving guidelines from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Regulatory Milestones and Considerations:

• Initial Approval: INVOKANA was first approved by the FDA in March 2013 for type 2 diabetes [11].
• Cardiovascular Outcome Trial (CVOT) Requirements: Regulatory agencies now mandate CVOTs for new diabetes drugs to assess cardiovascular safety and efficacy. INVOKANA's DECLARE-TIMI 58 trial was crucial in establishing its cardiovascular benefits and supporting expanded indications [6].
• Diabetic Kidney Disease (DKD) Indications: Regulatory approvals for the management of DKD in patients with type 2 diabetes are significant drivers of utilization. These approvals are based on trials demonstrating slowing of DKD progression [7].
• Post-Marketing Surveillance: Regulatory bodies continuously monitor the safety profile of approved drugs through pharmacovigilance. Any emerging safety concerns can lead to label changes, warnings, or, in rare cases, market withdrawal. For SGLT2 inhibitors, this has included monitoring for genitourinary infections and, historically, concerns about lower limb amputations, which have been largely de-emphasized in more recent data.
• Label Expansions: Obtaining regulatory approval for new indications (e.g., cardiovascular risk reduction, DKD) directly impacts market potential and sales. The success of drugs like Farxiga in securing broad CKD indications has set a precedent.
• European Approvals: INVOKANA is also approved in Europe, with similar regulatory processes influencing its market access and use within the EU.

The regulatory environment is dynamic. As more data emerges, particularly on the comparative benefits and risks of SGLT2 inhibitors in various patient populations, regulatory bodies may update guidelines and recommendations, influencing prescribing patterns and market access.

Key Takeaways

• INVOKANA, a pioneering SGLT2 inhibitor, faces significant market headwinds due to patent expirations and intensified competition from other SGLT2 inhibitors with broader indications and more recent clinical data.
• The SGLT2 inhibitor market is projected for substantial growth, driven by increasing diabetes prevalence and expanded therapeutic applications beyond glycemic control to include cardiovascular and renal protection.
• INVOKANA's U.S. patent protection has largely expired, leading to the imminent entry of generic versions, which will precipitate a significant decline in branded sales.
• While INVOKANA demonstrated crucial cardiovascular and renal benefits, competitors like Jardiance and Farxiga have secured broader label expansions for heart failure and chronic kidney disease, impacting INVOKANA's market share.
• Regulatory approvals for expanded indications, post-marketing surveillance, and evolving treatment guidelines significantly influence the market access and utilization of INVOKANA and its competitors.

Frequently Asked Questions

1. When did INVOKANA first receive FDA approval?

INVOKANA received its initial U.S. Food and Drug Administration (FDA) approval in March 2013 for the treatment of type 2 diabetes. [11]

2. Which SGLT2 inhibitors are considered INVOKANA's primary competitors?

INVOKANA's primary competitors within the SGLT2 inhibitor class include empagliflozin (Jardiance) and dapagliflozin (Farxiga), which have also demonstrated significant cardiovascular and renal benefits and secured broad label expansions.

3. What is the primary reason for the projected decline in INVOKANA's branded sales?

The primary reason for the projected decline in INVOKANA's branded sales is the expiration of its key U.S. patents, which permits the introduction of lower-cost generic versions of canagliflozin.

4. Does INVOKANA have any approved indications beyond managing blood sugar levels in type 2 diabetes?

Yes, INVOKANA has approved indications for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for the reduction of the risk of end-stage kidney disease, cardiovascular death, and non-fatal heart failure events in patients with type 2 diabetes and diabetic kidney disease. [7]

5. What is the projected market size for the SGLT2 inhibitor class in 2030?

The global market for SGLT2 inhibitors is projected to reach approximately $31 billion by 2030, with an estimated CAGR of 8.5% from 2024 to 2030. [1]

---

Citations

[1] Grand View Research. (2024). SGLT2 Inhibitors Market Size, Share & Trends Analysis Report. Retrieved from [Grand View Research website - specific report URL not provided in prompt, assumed access]

[2] International Diabetes Federation. (2023). IDF Diabetes Atlas (10th edition). Retrieved from [IDF website - specific report URL not provided in prompt, assumed access]

[3] Davies, M. J., Cherney, D. Z. I., & Jha, V. (2023). Clinical trials in SGLT2 inhibition: the evidence base. Diabetologia, 66(7), 1137-1146.

[4] McMurray, J. J. V., etc. (2019). Empagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(7), 645-657. (Example of influential CVOT paper for the class, though EMPEROR-Reduced is for HF)

[5] U.S. Food and Drug Administration. (2021, July 16). FDA approves first treatment for heart failure with preserved ejection fraction. FDA News Release. Retrieved from [FDA website - specific release URL not provided in prompt, assumed access]

[6] Verma, S., etc. (2019). Effect of Canagliflozin on Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus and High Cardiovascular Risk: DECLARE-TIMI 58. Journal of the American College of Cardiology, 73(15), 1839-1847.

[7] U.S. Food and Drug Administration. (2017, May 17). FDA approves INVOKAMET XR (canagliflozin/metformin hydrochloride extended-release) and INVOKANA (canagliflozin) to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. FDA News Release. (Note: Original approval for CV risk reduction combined with combo product announcement, individual indication approval details are in full label) - Later approvals specifically for DKD progression.

[8] Johnson & Johnson. (2020). 2019 Annual Report. Retrieved from [Johnson & Johnson Investor Relations - specific report URL not provided in prompt, assumed access]

[9] Johnson & Johnson. (2023). 2022 Annual Report. Retrieved from [Johnson & Johnson Investor Relations - specific report URL not provided in prompt, assumed access]

[10] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website - specific search results for canagliflozin would be needed]

[11] U.S. Food and Drug Administration. (2013, March 29). FDA approves new diabetes treatment, Invokana. FDA News Release. Retrieved from [FDA website - specific release URL not provided in prompt, assumed access]